OLMA Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. (OLMA) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.59 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -3.2% since its last earnings release on August 10, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.
Sector
Healthcare
Industry
Biotechnology